Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms- |
Target |
Action stimulants, antagonists |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), ROR1 antagonists(Inactive tyrosine-protein kinase transmembrane receptor ROR1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Triple Negative Breast Cancer | Preclinical | China | 01 Apr 2025 |